Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00988364 · ClinicalTrials.gov registry record · Phase 4
Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome.
A Phase 4 study, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT00988364 is a Phase 4 study that has completed, run by Baylor College of Medicine. The registered enrollment target is 30 participants.
The verdict
NCT00988364, a Phase 4 study, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is: * To identify the common factor for L5 prevalence in patients with Metabolic Syndrome. * To determine whether Ezetimibe, Simvastatin, and Vytorin can correct the L5- promoting factor and reduce L5 in Metabolic Syndrome patients.
Interventions
- DRUG Placebo
- DRUG Simvastatin
- DRUG Vytorin
- DRUG Ezetimibe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2007-03 |
| Est. Completion | 2008-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00988364
The ClinicalTrials.gov registry entry for NCT00988364 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00988364 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00988364 about?
NCT00988364 is a clinical study titled "Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome.". The purpose of this study is: * To identify the common factor for L5 prevalence in patients with Metabolic Syndrome. * To determine whether Ezetimibe, Simvastatin, and Vytorin can correct the L5- promoting factor and reduce L5 in Metabolic Syndrome patients.
What is the current status of trial NCT00988364?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2007-03. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00988364?
The interventions under investigation include: Placebo (DRUG), Simvastatin (DRUG), Vytorin (DRUG), Ezetimibe (DRUG).
Who is sponsoring clinical trial NCT00988364?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.